Entry

D11875                      Drug

Name

Ansuvimab (USAN);
Ansuvimab-zykl;
Ebanga (TN)

Product

EBANGA (Ridgeback Biotherapeutics)

Formula

C6368H9924N1724O1994S44

Exact mass

143859.5861

Mol weight

143948.1486

Sequence

(Heavy chain)
EVQLVESGGG LIQPGGSLRL SCAASGFALR MYDMHWVRQT IDKRLEWVSA VGPSGDTTYA
DSVKGRFAVS RENAKNSLSL QMNSLTAGDT AIYYCVRSDR GVAGLFDSWG QGILVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(Light chain)
DIQMTQSPSS LSASVGDRIT ITCRASQAFD NYVAWYQQRP GKVPKLLISA ASALHAGVPS
RFSGSGSGTH FTLTISSLQP EDVATYYCQN YNSAPLTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H95, H146-H202, H222-L214, H228-H'228, H231-H'231, H263-H323, H369-H427, H'22-H'95, H'146-H'202, H'222-L'214, H'263-H'323, H'369-H'427, L23-L88, L134-L194, L'23-L'88, L'134-L'194)

Type

Peptide

Remark

Product:

D11875<US>

Efficacy

Antiviral

Disease

Zaire ebolavirus infection [DS:H00283]

Comment

Monoclonal antibody
Treatment of Ebola virus

Target

Zaire ebolavirus glycoprotein GP1 [KO:K24534]

Pathway

ko03230

Viral genome structure

Brite

Antimicrobials [BR:br08307]
Antivirals
  Entry, fusion or uncoating inhibitor
   Ebolavirus glycoprotein
    D11875  Ansuvimab (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11875
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11875

Other DBs

CAS:	2266625-91-4